BIPAR SCIENCES
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Ven... ture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.
BIPAR SCIENCES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.biparsciences.com
Total Employee:
11+
Status:
Active
Contact:
650-635-6050
Total Funding:
74.97 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Mobile Non Scaleable Content Nginx Baidu Analytics DNS.COM
Current Employees Featured
Founder
Investors List
Vulcan Capital
Vulcan Capital investment in Series C - BiPar Sciences
Canaan Partners
Canaan Partners investment in Series C - BiPar Sciences
PolyTechnos Venture Partners
PolyTechnos Venture Partners investment in Series C - BiPar Sciences
Asset Management Company
Asset Management Company investment in Series C - BiPar Sciences
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series C - BiPar Sciences
Domain Associates
Domain Associates investment in Series C - BiPar Sciences
Quantum Technology Partners
Quantum Technology Partners investment in Series C - BiPar Sciences
Sand Hill Angels
Sand Hill Angels investment in Series B - BiPar Sciences
Asset Management Company
Asset Management Company investment in Series B - BiPar Sciences
Sand Hill Angels
Sand Hill Angels investment in Series A - BiPar Sciences
Official Site Inspections
http://www.biparsciences.com
- Host name: 83.229.75.207
- IP address: 83.229.75.207
- Location: Nigeria
- Latitude: 10
- Longitude: 8
- Timezone: Africa/Lagos
More informations about "BiPar Sciences"
BiPar Sciences - Crunchbase Company Profile & Funding
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in …See details»
New Executive Leadership and CEO Announced for BiPar Sciences
BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. ... For more …See details»
BiPar Sciences, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Jul 12, 2023 Explore BiPar Sciences, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, and 2 literature, Drug:BSI-401, BSI-301.See details»
New Executive Leadership and CEO Announced for BiPar Sciences
Dec 16, 2009 BiPar Chief Executive Officer and President Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of …See details»
New Executive Leadership and CEO Announced for BiPar
Dec 11, 2009 BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. ... For …See details»
BiPar Sciences, Inc. - Brisbane, USA - bionity.com
Jul 20, 2009 biparsciences.com +1650635-6050. Share. Xing Linkedin Facebook X E-mail Loading... Bookmark. Bookmark list; Bookmark. BiPar Sciences, Inc. 1000 Marina Blvd., Suite …See details»
BiPar Sciences - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for BiPar Sciences. Use the PitchBook Platform to explore the full profile.See details»
BiPar Sciences - Overview, News & Similar companies - ZoomInfo
BiPar Sciences Inc. (www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-sel ective drugs designed to meet the …See details»
BiPar Sciences - Ownership and Business Overview - Mergr
Apr 15, 2009 www.biparsciences.com. Profile Investors (2) Analytics BiPar Sciences, Inc. is a biopharmaceutical company developing and commercializing potential new classes of tumor …See details»
New Executive Leadership and CEO Announced for BiPar
Dec 11, 2009 Best Places to Work; Employer Resources; Post Jobs; Talent Solutions; Advertise; Submit a Press ReleaseSee details»
BiPar Sciences - VentureRadar
"BiPar Sciences, Inc. develops small molecules for the inhibition of PARP pathways. Indications which have been explored include triple negative breast cancer, ovarian cancer and several …See details»
SANOFI SYN ADR : New Executive Leadership and CEO Announced …
Dec 11, 2009 ca5e5bb5e2e43787e6957f11e737a6.HcLacbgqt-E4_zloJrn_8JVuabw0GsVYtnMjA7CvnCo.a4e …See details»
BiPar Sciences - LinkedIn
BiPar Sciences | 95 followers on LinkedIn. BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors ...See details»
BiPar Sciences - Products, Competitors, Financials, Employees ...
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, …See details»
BiPar Sciences, Inc. Expands Management Team to Advance Lead …
BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has …See details»
Sanofi-Aventis To Acquire BiPar Sciences
Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., ("BiPar") a privately held US biopharmaceutical company, developing …See details»
BiPar Sciences, Inc. Asset Profile | Preqin
BiPar is a clinical-stage drug development company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients.See details»
BiPar Sciences, Inc. Announces Upcoming Data Presentations
BRISBANE, Calif., Oct. 22 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that key …See details»
SANOFI-AVENTIS : BiPar Sciences Announces Update on the …
Dec 14, 2009 PR Newswire/Les Echos/ Press Release BiPar Sciences Announces Update on the Clinical Development Progress of BSI-201 for Metastatic Triple-Negative Breast Cancer - …See details»
BiPar Sciences, Inc. Begins Phase 2 Study of Lead PARP ... - BioSpace
Nov 15, 2007 BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer …See details»